Intellia Therapeutics Newsroom

Intellia Doses First Patient in Phase 3 Trial of Potential Treatment for Hereditary Angioedema

MT NewswiresJan 22 10:42 ET

Express News | Intellia Therapeutics Inc - Expects to Complete Enrollment in Phase 3 Study by H2 2025

ReutersJan 22 07:30 ET

Express News | Intellia Therapeutics Announces First Patient Dosed in the Haelo Phase 3 Study of Ntla-2002, an Investigational in Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

ReutersJan 22 07:30 ET

Cathie Wood's Ark Invest Buys Into Defense And Energy Stocks Amid Trump's Inaugural Policies

BenzingaJan 22 04:47 ET

Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases

BenzingaJan 22 01:44 ET

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

Intellia TherapeuticsJan 22 00:00 ET

Insiders At Intellia Therapeutics Sold US$975k In Stock, Alluding To Potential Weakness

Simply Wall StJan 20 05:47 ET

Intellia Loses 21.6% in a Week: How Should You Play the Stock?

Zacks Jan 17 13:00 ET

BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $45

Moomoo NewsJan 14 10:32 ET · Ratings

Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $12

Moomoo NewsJan 14 10:32 ET · Ratings

Express News | Goldman Sachs Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $12

BenzingaJan 14 09:10 ET

A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $40 to $45

Moomoo NewsJan 14 08:00 ET · Ratings

Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), CareDx (CDNA) and Intellia Therapeutics (NTLA)

TipRanksJan 14 06:30 ET · Ratings

Oppenheimer Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $40

BenzingaJan 13 11:08 ET · Ratings

Express News | Intellia Therapeutics Inc : Jefferies Cuts Target Price to $86 From $128

ReutersJan 13 00:15 ET

Express News | Intellia Therapeutics Inc : Oppenheimer Cuts Target Price to $40 From $60

ReutersJan 13 00:04 ET

BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $50

Moomoo NewsJan 11 11:31 ET · Ratings

Strategic Focus and Financial Resilience: Terence Flynn's Positive Outlook on Intellia Therapeutics

TipRanksJan 11 10:36 ET

Barclays Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $55

Moomoo NewsJan 11 10:32 ET · Ratings

Analysts' Top Healthcare Picks: Inozyme Pharma (INZY), Intellia Therapeutics (NTLA)

TipRanksJan 11 10:30 ET · Ratings